Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

Acute Necrotizing Pancreatitis Following Olanzapine Treatment and 759C/T Polymorphism of HTR2C Gene: A Case Report.

Rizos E, Tournikioti K, Alevyzakis E, Peppa M, Papazaxos K, Zorbas G, Michopoulos I, Liappas I, Papageorgiou C, Douzenis A.

In Vivo. 2015 Sep-Oct;29(5):529-31.

PMID:
26359410
2.

Atypical Antipsychotics and the Risk of Hyperlipidemia: A Sequence Symmetry Analysis.

Takeuchi Y, Kajiyama K, Ishiguro C, Uyama Y.

Drug Saf. 2015 Jul;38(7):641-50. doi: 10.1007/s40264-015-0298-4.

PMID:
26001933
3.

The incidence of dyslipidemia (hypertriglyceridemia and hypercholesterolemia) in patients treated with the new generation of antipsychotic drugs compared to conventional therapy.

Sadibašić B, Macić-Džanković A, Šabić A, Torlak B, Lastrić G, Ćustović A.

Med Glas (Zenica). 2014 Aug;11(2):350-5.

PMID:
25082252
4.

Olanzapine-induced triglyceride and aminotransferase elevations without weight gain or hyperglycemia normalized after switching to aripiprazole.

Pawelczyk T, Pawelczyk A, Rabe-Jablonska J.

J Psychiatr Pract. 2014 Jul;20(4):301-7. doi: 10.1097/01.pra.0000452568.92449.3f.

PMID:
25036587
5.

The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic β cells by blocking PERK-mediated translational attenuation.

Ozasa R, Okada T, Nadanaka S, Nagamine T, Zyryanova A, Harding H, Ron D, Mori K.

Cell Struct Funct. 2013;38(2):183-95. Epub 2013 Jun 28. Erratum in: Cell Struct Funct. 2014;39(1):21. Cell Struct Funct. 2013;38(2):227.

6.

Prescription of second-generation antipsychotics: responding to treatment risk in real-world practice.

Hermes ED, Sernyak MJ, Rosenheck RA.

Psychiatr Serv. 2013 Mar 1;64(3):238-44. doi: 10.1176/appi.ps.201200183.

PMID:
23241613
7.

Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.

Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C.

J Clin Psychopharmacol. 2012 Jun;32(3):309-16. doi: 10.1097/JCP.0b013e3182549259. Review.

PMID:
22544019
8.

Switching antipsychotic medications: not enough, too often, or just right?

Weiden PJ.

Am J Psychiatry. 2011 Sep;168(9):882-4. doi: 10.1176/appi.ajp.2011.11060958. No abstract available.

PMID:
21890800
9.

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).

Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA; Schizophrenia Trials Network.

Am J Psychiatry. 2011 Sep;168(9):947-56. doi: 10.1176/appi.ajp.2011.10111609. Epub 2011 Jul 18.

10.

Using structural equations to test for a direct effect of some antipsychotics on triglyceride levels in drug-naïve first-episode psychosis patients.

Diaz FJ, Perez-Iglesias R, Mata I, Martínez-Garcia O, Vázquez-Barquero JL, de Leon J, Crespo-Facorro B.

Schizophr Res. 2011 Sep;131(1-3):82-9. doi: 10.1016/j.schres.2011.06.006. Epub 2011 Jul 2.

PMID:
21726981
11.

Diabetes prevalence estimates in schizophrenia and risk factor assessment.

Argo T, Carnahan R, Barnett M, Holman TL, Perry PJ.

Ann Clin Psychiatry. 2011 May;23(2):117-24.

PMID:
21547272
12.

Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment.

Hong CJ, Chen TT, Bai YM, Liou YJ, Tsai SJ.

World J Biol Psychiatry. 2012 Jan;13(1):22-9. doi: 10.3109/15622975.2010.551543. Epub 2011 Mar 4.

PMID:
21375366
13.

Management of schizophrenia in children and adolescents: focus on pharmacotherapy.

Masi G, Liboni F.

Drugs. 2011 Jan 22;71(2):179-208. doi: 10.2165/11585350-000000000-00000. Review.

PMID:
21275445
14.

Off-label second generation antipsychotics for impulse regulation disorders: a review.

Scheltema Beduin A, de Haan L.

Psychopharmacol Bull. 2010;43(3):45-81. Review.

PMID:
21150846
15.

Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.

Smith RC, Lindenmayer JP, Hu Q, Kelly E, Viviano TF, Cornwell J, Vaidhyanathaswamy S, Marcovina S, Davis JM.

Schizophr Res. 2010 Jul;120(1-3):204-9. doi: 10.1016/j.schres.2010.04.001. Epub 2010 May 10.

PMID:
20457512
16.

Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population.

Duncan EJ, Woolson SL, Hamer RM, Dunlop BW.

Int Clin Psychopharmacol. 2009 Jul;24(4):204-13. doi: 10.1097/YIC.0b013e32832d6c18.

PMID:
19494785
17.

Metabolic risks in older adults receiving second-generation antipsychotic medication.

Brooks JO 3rd, Chang HS, Krasnykh O.

Curr Psychiatry Rep. 2009 Feb;11(1):33-40. Review.

PMID:
19187706
18.
19.

Atypical antipsychotics: new drugs, new challenges.

Mathews M, Muzina DJ.

Cleve Clin J Med. 2007 Aug;74(8):597-606. Review.

PMID:
17708131
20.

A clinical study of the association of antipsychotics with hyperlipidemia.

de Leon J, Susce MT, Johnson M, Hardin M, Pointer L, Ruaño G, Windemuth A, Diaz FJ.

Schizophr Res. 2007 May;92(1-3):95-102. Epub 2007 Mar 8.

PMID:
17346932
Items per page

Supplemental Content

Loading ...
Write to the Help Desk